Lymecycline

 Eur J Dermatol. 2003 Mar-Apr;13(2):130-5.

Lymecycline in the treatment of acne: an efficacious, safe and cost-effective alternative to minocycline.

Bossuyt L, Bosschaert J, Richert B, Cromphaut P, Mitchell T, Al Abadie M, Henry I, Bewley A, Poyner T, Mann N, Czernielewski J.

    Leon Spiliarstraat 18A, 8400 Oostende, Belgium.

A comparison of efficacy, safety and cost-effectiveness of lymecycline and minocycline in the treatment of acne vulgaris has been addressed. This was a multicenter, randomized, investigator-masked, parallel group trial involving patients with moderate to moderately severe acne vulgaris, receiving either lymecycline or minocycline for 12 weeks. Efficacy and safety evaluation was performed at baseline and at weeks 4, 8, and 12 and completed by a pharmacoeconomic analysis including week 12 data. One hundred and thirty-six patients were enrolled. At week 12, the mean percent reductions in inflammatory count were 63 % and 65 %, and for total lesions counts 58 % and 56 % for lymecycline and for minocycline respectively. Median percent reduction in non-inflammatory count were 54 % and 47 % for lymecycline and for minocycline respectively. Eighty-seven per cent of all patients tolerated the treatments well. Treatment with lymecycline was found to be 4 times more cost-effective than with minocycline. Results showed that lymecycline has a comparable efficacy and safety profile to minocycline while being 4 times more cost-effective.

    Publication Types:

    * Clinical Trial
    * Multicenter Study
    * Randomized Controlled Trial

PMID: 12695127 [PubMed - indexed for MEDLINE]

--------------------------------------

http://www.medsafe.govt.nz/profs/Data***/t/Tetralysalcap.htm

*Actions*

Tetralysal (lymecycline) is a tetracycline chemically bonded to the amino acid L-lysine. It has been estimated that 408 mg of lymecycline, equivalent to 300 mg tetracycline base, is equivalent in its action to 500 mg tetracycline hydrochloride. Lymecycline is approximately 5000 times more soluble than tetracycline base and unlike tetracycline hydrochloride it is soluble at all physiological pH values ( a 5% aqueous solution does not precipitate in the presence of serum).

*Pharmacokinetics*

The Tetralysal (lymecycline) molecule is distinguished by a monoamino-mono-carboxylic acid substituent at C-2 which provides it with important characteristics bearing on clinical effect. Tetralysal(lymecycline) is unique amongst tetracyclines in that it is absorbed by the "active transport" process. Carrier enzymes within the intestinal wall interact with the drug molecules and draw them into the membrane. Passing from one enzyme molecule to the next, the Tetralysal (lymecycline) molecule is carried through the lipid barrier to be liberated on the other side of the membrane. This method of absorption is fast and efficient. It is the method by which carbohydrates are absorbed.

Tetralysal (lymecycline) is stable at all body pH values (from pH 2 to pH 7.5), high serum tissue and urine levels.
.

Quantcast